References
- JankovicJSchwartzKResponse and immunoresistance to botulinum toxin injectionsNeurology1995459174317467675238
- DresslerDClinical presentation and management of antibody-induced failure of botulinum toxin therapyMov Disord200419Suppl 8S9210015027060
- GreenePFahnSDiamondBDevelopment of resistance to botulinum toxin type A in patients with torticollisMov Disord1994922132178196686
- JankovicJVuongKDAhsanJComparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystoniaNeurology20036071186118812682332
- MullerKMixEAdib SaberiFDresslerDBeneckeRPrevalence of neutralising antibodies in patients treated with botulinum toxin type A for spasticityJ Neural Transm2009116557958519352590
- BrinMFComellaCLJankovicJLaiFNaumannMLong-term treatment with botulinum toxin type A in cervical dystonia has low immunogenicity by mouse protection assayMov Disord200823101353136018546321
- LangeOBigalkeHDenglerRWegnerFdeGrootMWohlfarthKNeutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: Much ado about nothing?Clin Neuropharmacol200932421321819620852
- BorodicGImmunologic resistance after repeated botulinum toxin type A injections for facial rhytidesOphthal Plast Reconstr Surg2006223239240
- LeeSKAntibody-induced failure of botulinum toxin type A therapy in a patient with masseteric hypertrophyDermatol Surg2007331 Spec NoS10511017278332
- GöschelHWohlfarthKFrevertJDenglerRBigalkeHBotulinum A toxin therapy: Neutralizing and nonneutralizing antibodies – therapeutic consequencesExp Neurol19971471961029294406
- LeeJCYokotaKArimitsuHProduction of anti-neurotoxin antibody is enhanced by two subcomponents, HA1 and HA3b, of Clostridium botulinum type B 16S toxin-haemagglutininMicrobiology2005151Pt 113739374716272395
- CarruthersACarruthersJBotulinum toxin products overviewSkin Therapy Lett20081361418806905
- FlynnTCClarkRE2ndBotulinum toxin type B (Myobloc) versus botulinum toxin type A (Botox) frontalis study: Rate of onset and radius of diffusionDermatol Surg200329551952212752521
- FlynnTCBotulinum toxin: Examining duration of effect in facial aesthetic applicationsAm J Clin Dermatol201011318319920369902
- KawashimaMHariiKAn open-label, randomized, 64-week study repeating 10- and 20-U doses of botulinum toxin type A for treatment of glabellar lines in Japanese subjectsInt J Dermatol200948776877619490208
- LawrenceIMoyRAn evaluation of neutralizing antibody induction during treatment of glabellar lines with a new US formulation of botulinum neurotoxin type AAesthet Surg J2009296 SupplS667119945007
- MonheitGCarruthersABrandtFRandRA randomized, double-blind, placebo-controlled study of botulinum toxin type A for the treatment of glabellar lines: Determination of optimal doseDermatol Surg2007331 Spec NoS515917241415
- ChengCMChenJSPatelRPUnlabeled uses of botulinum toxins: A review, Part 1Am J Health Syst Pharm200663214515216390928
- ChengCMChenJSPatelRPUnlabeled uses of botulinum toxins: A review, Part 2Am J Health Syst Pharm200663322523216434781